short bowel syndrome: Clinical Insights for Gut Health

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptides offer a promising therapeutic avenue for short bowel syndrome by enhancing nutrient absorption and promoting intestinal adaptation. These agents can significantly improve patient outcomes by reducing dependence on parenteral nutrition.

```html

Peptides for Short Bowel Syndrome

Approximately 10,000 to 20,000 individuals in the United States live with short bowel syndrome (SBS), a complex malabsorptive disorder resulting from extensive surgical resection of the small intestine. This condition often leads to chronic diarrhea, dehydration, malnutrition, and dependence on parenteral nutrition (PN). While traditional management focuses on dietary modifications, anti-diarrheal agents, and PN, emerging peptide therapies offer a promising avenue to enhance intestinal adaptation and reduce PN requirements.

Understanding Intestinal Adaptation in SBS

The remaining small intestine in SBS patients possesses a remarkable capacity for adaptation. This involves structural changes, such as villous hypertrophy and increased crypt depth, and functional changes, including enhanced nutrient absorption. However, this adaptive process is often insufficient to restore full digestive and absorptive capacity, particularly in cases with less than 100 cm of residual small bowel or absence of the colon. The goal of peptide-based therapies is to stimulate and accelerate this intrinsic adaptive response.

Teduglutide: A GLP-2 Analog

Teduglutide, a glucagon-like peptide-2 (GLP-2) analog, stands as the most established peptide therapy for SBS. GLP-2 is an endogenous hormone secreted by enteroendocrine cells in response to nutrient ingestion. It plays a crucial role in maintaining intestinal integrity and promoting growth. Teduglutide mimics these actions, stimulating mucosal growth, increasing villus height, and enhancing intestinal blood flow. This leads to improved fluid and nutrient absorption.

Clinical trials have demonstrated teduglutide's efficacy. In the STEPS-2 study (Jeppesen et al., 2012), adult SBS patients receiving 0.05 mg/kg of teduglutide subcutaneously once daily experienced a significant reduction in PN volume by 4.4 liters per week after 24 weeks, compared to a 1.7-liter reduction in the placebo group. Furthermore, 63% of teduglutide-treated patients achieved a 20% or greater reduction in PN volume, versus 30% in the placebo group. Some patients even achieved complete PN independence. While most patients respond positively, a subset doesn't achieve significant PN reduction. This often correlates with very short residual bowel length (e.g., less than 50 cm) or the presence of high-output stomas, where the adaptive capacity is severely limited.

Other Peptides Under Investigation

Beyond teduglutide, several other peptides are being explored for their potential in SBS management:

• Growth Hormone (GH): Historically, GH was investigated for SBS, often in combination with glutamine and a modified diet. Early studies, like that by Scolapio et al. (1997), showed some promise in reducing PN requirements. However, the high cost, potential side effects (e.g., arthralgia, carpal tunnel syndrome, glucose intolerance), and inconsistent long-term benefits have limited its widespread use. Teduglutide generally offers a more favorable risk-benefit profile and is often preferred over GH due to its targeted action on the gut.
• GLP-1 Receptor Agonists: While GLP-1 primarily regulates glucose homeostasis and gastric emptying, its role in intestinal adaptation is being explored. Some research suggests GLP-1 may indirectly influence intestinal growth and function. However, its primary effect of slowing gastric emptying could be detrimental in SBS patients already struggling with nutrient absorption, making its direct application more complex than GLP-2.
• Epidermal Growth Factor (EGF): EGF is a potent mitogen for intestinal epithelial cells. Preclinical studies have shown that EGF can promote intestinal growth and repair. However, translating these findings into effective and safe clinical therapies for SBS has proven challenging, largely due to concerns about systemic side effects and the optimal delivery method.
• Ghrelin Agonists: Ghrelin, known as the "hunger hormone," also has trophic effects on the gastrointestinal tract. Agonists are being investigated for their potential to stimulate appetite and promote intestinal adaptation, particularly in patients with significant weight loss and malnutrition.

Clinical Considerations and Nuance

The decision to initiate peptide therapy, particularly teduglutide, involves careful patient selection. Patients with a colon in continuity generally respond better than those with an end-stoma, as the colon plays a significant role in fluid and electrolyte absorption. Baseline PN requirements and the presence of complications like liver disease or recurrent line